AOP Orphan Pharmaceuticals GmbH (AOP Health) has received FDA approval for Rapiblyk™ (landiolol), a treatment for supraventricular tachycardia (atrial fibrillation and atrial flutter) in intensive care settings. This ultra-short-acting beta-blocker provides rapid heart rate reduction with minimal impact on blood pressure. Approval was based on five clinical studies involving 317 patients, demonstrating a significant efficacy compared to placebo. Side effects, primarily hypotension, were observed in 9.9% of treated patients. The drug is already available in Europe and marks a milestone in intensive care treatment options for U.S. patients.